Ionis Pharmaceuticals — Jan 12, 2026 release

“This momentum is further bolstered by the promise of our late-stage Ionis owned and partnered programs, with a total of five Phase 3 readouts and four NDA submissions anticipated this year. With strong execution and multiple key catalysts expected, Ionis is well-positioned to deliver accelerating revenue growth to achieve cash flow breakeven in 2028.” Preliminary TRYNGOLZA ® (olezarsen) 2025 Full Year U.S. Net Sales • TRYNGOLZA outperformed expectations as the first U.S. Food and Drug Administration (FDA)-approved treatment for familial chylomicronemia syndrome (FCS), generating $105* million in preliminary U.S. net product sales in 2025 2026 Anticipated Highlights   Include : Ionis Owned Programs • Potential approval and launch of olezarsen as the new standard of care for severe hypertriglyceridemia (sHTG) o Submitted U.S. Supplemental New Drug Application (sNDA), following receipt of Breakthrough Therapy Designation ■ Olezarsen achieved a highly statistically significant placebo-adjusted reduction of up to 72% in fasting triglycerides and an 85% reduction in acute pancreatitis events with favorable safety and tolerability in pivotal Phase 3 CORE and CORE2 studies o Increasing annual olezarsen peak net sales guidance to >$2 billion from >$1 billion based on strong product profile and positive Phase 3 data 1 • Continued early positive momentum with the launch